CABALETTA BIO, INC. (CABA) Current Ratio
- Current ratio · latest quarter: Value 5.79×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.79× | Current assets / current liabilities. $231.03M ÷ $39.91M ≈ 5.79× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 231.03M USD | Assets, Current |
| Current obligations | 39.91M USD | Liabilities, Current |
| Cash and equivalents | 225.10M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 5.81M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $231.03M | $39.91M | $225.10M | (m) | (m) | (m) | $5.81M | (m) | 5.79× |
| 2026-03-31 | $122.32M | $41.51M | $116.64M | (m) | (m) | (m) | $6.38M | (m) | 2.95× |
| 2025-12-31 | $138.87M | $50.15M | $82.98M | (m) | (m) | (m) | $6.64M | (m) | 2.77× |
| 2025-09-30 | $164.56M | $45.73M | $60.21M | (m) | (m) | (m) | $8.27M | (m) | 3.60× |
| 2025-06-30 | $198.41M | $41.54M | $145.61M | (m) | (m) | (m) | $7.19M | (m) | 4.78× |
| 2025-03-31 | $134.60M | $33.99M | $131.83M | (m) | (m) | (m) | $6.49M | (m) | 3.96× |
| 2024-12-31 | $166.68M | $27.09M | $163.96M | (m) | (m) | (m) | $4.92M | (m) | 6.15× |
| 2024-09-30 | $185.51M | $22.88M | $170.61M | (m) | (m) | (m) | $2.18M | (m) | 8.11× |
| 2024-06-30 | $206.26M | $17.90M | $178.61M | (m) | (m) | (m) | $4.22M | (m) | 11.52× |
| 2024-03-31 | $227.48M | $17.97M | $175.29M | (m) | (m) | (m) | $5.84M | (m) | 12.66× |
| 2023-12-31 | $244.49M | $15.99M | $193.24M | (m) | (m) | (m) | $4.55M | (m) | 15.29× |
| 2023-09-30 | $166.18M | $10.62M | $115.50M | (m) | (m) | (m) | $3.62M | (m) | 15.65× |
| 2023-06-30 | $177.57M | $8.48M | $128.07M | (m) | (m) | (m) | $2.34M | (m) | 20.94× |
| 2023-03-31 | $95.73M | $9.30M | $93.84M | (m) | (m) | (m) | $3.96M | (m) | 10.29× |
| 2022-12-31 | $108.83M | $9.49M | $81.61M | (m) | (m) | (m) | $2.46M | (m) | 11.47× |
| 2022-09-30 | $88.17M | $5.80M | $61.16M | (m) | (m) | (m) | $1.33M | (m) | 15.20× |
| 2022-06-30 | $98.75M | $6.49M | $47.17M | (m) | (m) | (m) | $2.45M | (m) | 15.22× |
| 2022-03-31 | $111.44M | $6.93M | $59.55M | (m) | (m) | (m) | $3.91M | (m) | 16.07× |
| 2021-12-31 | $124.54M | $8.38M | $122.22M | (m) | (m) | (m) | $2.33M | (m) | 14.86× |
| 2021-09-30 | $120.85M | $6.02M | $118.26M | (m) | (m) | (m) | $1.71M | (m) | 20.07× |
| 2021-06-30 | $105.02M | $5.60M | $99.50M | (m) | (m) | (m) | $2.37M | (m) | 18.75× |
| 2021-03-31 | $105.76M | $3.97M | $97.28M | (m) | (m) | (m) | $1.27M | (m) | 26.65× |
| 2020-12-31 | $113.53M | $5.18M | $101.43M | (m) | (m) | (m) | $1.24M | (m) | 21.92× |
| 2020-09-30 | $119.22M | $4.26M | $108.68M | (m) | (m) | (m) | $953.00K | (m) | 27.95× |
| 2020-06-30 | $123.47M | $3.26M | $112.10M | (m) | (m) | (m) | $991.00K | (m) | 37.84× |
| 2020-03-31 | $134.12M | $3.26M | $131.00M | (m) | (m) | (m) | $1.99M | (m) | 41.19× |
| 2019-12-31 | $140.55M | $3.15M | $136.20M | (m) | (m) | (m) | $920.00K | (m) | 44.66× |
| 2019-09-30 | $71.75M | $3.06M | $71.04M | (m) | (m) | (m) | $1.15M | (m) | 23.42× |
| 2018-12-31 | $33.99M | $943.00K | $33.02M | (m) | (m) | (m) | $603.00K | (m) | 36.05× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |